Abstract
This study was undertaken to compare and verify the antihypertensive effects of various delapril doses versus placebo on office and ambulatory blood pressure (BP). After a 2-wk placebo period, 303 patients with mild to moderate essential hypertension were randomized in a double-blind study to 8 wk of treatment with placebo, or delapril 7.5 mg twice daily, delapril 15 mg twice daily, delapril 30 mg twice daily, or delapril 30 mg once daily. BP changes versus baseline and rates of normalized office systolic blood pressure (SBP) > 140 mm Hg and diastolic blood pressure (DBP) > 90 mm Hg, as well as responder office SBP > 140 mm Hg or reduction ≥20 mm Hg and office DBP > 90 mm Hg or reduction ≥10 mm Hg, were calculated. In the intention-to-treat population (n=296), office SBP and DBP reductions were more notable with 30 mg twice daily (15.6/11.5 mm Hg) and 15 mg twice daily (14.8/12.5 mm Hg) than with other delapril regimens (30 mg once daily: 11.8/10.5 mm Hg; 7.5 mg twice daily: 12.9/10.1 mm Hg) and placebo (P< .05 for DBP;P< .01 for SBP). The same was true for frequency of responders (63.8% and 60.3%; P≤.05 vs placebo) and normalized patients (58.6% and 53.4%;P< .05 vs placebo). Analysis of ambulatory BPs confirmed the accuracy of office BPs. Drug-related adverse events occurred in 3.4% to 6.7% of patients given delapril and in 6.5% of those given placebo. The lowest effective dose of delapril, 15 mg twice daily, may be recommended as the initial dose for patients who begin treatment with this agent.
Similar content being viewed by others
References
Onoyama K, Nanishi F, Okuda S, et al. Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (delapril) in patients with deteriorated kidney function and in normal control subjects.Clin Pharmacol Ther. 1988;43:242–249.
The GLANT Study Group. A 12-month comparison of ACE inhibitor and Ca antagonist therapy in mild to moderate essential hypertension—The GLANT study.Hypertens Res. 1995;18:235–244.
Ogihara T. Practitioner’s trial on the efficacy of antihypertensive treatment in the elderly with hypertension (the PATE-Hypertension Study) in Japan.Am J Hypertens. 2000;13:461–467.
Ogihara T, Kaneko Y, Ikeda M, et al. Clinical evaluation of delapril in Japan. Report from the Japan study group on delapril.Am J Hypertens. 1991;4:42S-45S.
Rahn KH. Comparison of the antihypertensive effects of delapril and enalapril.Am J Hypertens. 1991;4:38S-41S.
Arakawa K. Clinical effect of delapril hydrochloride (CV-3317) monotherapy in the treatment of essential hypertension.J Clin Ther Med. 1987;3:307.
Dalla-Volta S. Safety and efficacy study of delapril versus enalapril in patients with congestive heart failure.Am J Cardiol. 1995;75:44F-49F.
Circo A, Platania F, Mangiameli S, Putignano E. Multicenter, randomized, placebo-controlled, double-blind study of the safety and efficacy of oral delapril in patients with congestive heart failure.Am J Cardiol. 1995;75:18F-24F.
Omboni S, Fogari R, Mancia G. A smooth blood pressure control is obtained over 24 h by delapril in mild to moderate essential hypertensives.Blood Press. 2001;10:170–175.
Fogari R, Zoppi A, Mugellini A, Vanasia A, Poletti L, Corradi L. Efficacy of delapril in the treatment of mild to moderate essential hypertension: evaluation by 24-hour ambulatory blood pressure monitoring.Adv Ther. 1997;14:254–261.
Rosiello G, et al. Antihypertensive efficacy of delapril administered according to a twice daily and UID dosage scheme. Assessment by out-patient pressure monitoring.La Presse Medicale. 1995;9:240.
The European Agency for the Evaluation of Medicinal Products (EMEA).CPMP Guidelines. London, United Kingdom: EMEA; 1994:1–11.
Guidelines Subcommittee, 1999 World Health Organisation. International Society of Hypertension Guidelines for the Management of Hypertension.J Hypertens. 1999;17:151–183.
Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.Hypertension. 2003;42:1206–1252.
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Otero, M.L., Parisi, G., Maffei, A. et al. Assessment of the antihypertensive efficacy of various doses of delapril by office and ambulatory blood pressure measurement: The DEFIND study. Adv Therapy 23, 421–432 (2006). https://doi.org/10.1007/BF02850163
Issue Date:
DOI: https://doi.org/10.1007/BF02850163